In certain circumstances, data abstracted from electronic medical records can be used to predict an impending clinical condition ([@bib9]). The prescreening triage paradigm we propose here is applicable to diseases where early diagnosis is relevant to halt the progression from subclinical to frank disease ([@bib1]; [@bib3]; [@bib19]; [@bib15]). For colorectal cancer (CRC), early diagnosis has been shown to be beneficial and screening is routinely recommended to adults ([@bib1]). Colonoscopy is effective but is costly and many consider colonoscopy to be inefficient as a population-wide screening tool ([@bib7]). In Israel, all adults are offered screening for occult blood loss using the faecal immunochemical testing (FIT) annually ([@bib23]). However, adherence to FIT screening and compliance with colonoscopy after a positive FIT test are suboptimal. Approximately 56% of eligible Israeli residents reported having had a colonoscopy in the past 10 years or an FIT test in the past year ([@bib13]). Adherence may be enhanced if individuals can be stratified into a high-risk group; that is, to identify men and women who have a higher than average risk of CRC for screening colonoscopy.

We have previously described MeScore, a machine learning-based algorithm, using historical complete blood counts, sex and age, and documented its performance in identifying patients with CRC ([@bib12]). In the current study, we evaluate the potential for using the results of all lab tests, including complete blood counts, obtained in the course of routine clinical care and recorded in an electronic health records database. We analysed the medical record database of a large HMO in Israel and linked these electronic records with the Israeli Cancer Registry.

Materials and methods
=====================

Study population
----------------

Macabbi Health Services (MHS) is the second largest HMO in Israel with approximately two million enrollees. We abstracted information on the patient population from MHS electronic medical record database, including demographic data (sex and date of birth) and the results of all blood tests conducted from January 2001 until the end of 2011.

Cases were MHS enrollees who were diagnosed with CRC between 40 and 75 years of age between 2002 and 2011. To be included in this study, cases had to have had at least one blood test recorded in MHS electronic medical records before the date of diagnosis (index date). Individuals with a history of CRC or with another form of cancer before 2002 were excluded from the analysis. The diagnosis of CRC among MHS patients was made through linkage to the Israeli Cancer Registry using a unique national identifier.

Controls were selected from among all individuals in MHS registry who did not have any cancer, according to the Israeli Cancer Registry. Control subjects were matched to cases based on sex and year of birth. Controls were required to have had at least one blood test before the index date of the matched case. All controls were iteratively matched with cases, resulting in a fixed ratio of 45 controls per case ([Table 1](#tbl1){ref-type="table"}).

Data were taken from the results of the blood tests extracted from the patients\' electronic medical records. All blood tests were analysed at a single national lab. The blood tests were ordered for a variety of reasons, including routine health examination and for specific clinical indications, but we did not have details regarding the specific indication. We included all blood analytes in our initial analyses, provided that the test had been conducted on a minimum of 10% of the controls. For the purposes of this study, the index blood test was defined as one that was carried out from 1 to 6 months before the date of diagnosis of CRC in the cases or the index date for controls. In the event that more than one blood test was carried out during this interval, the most recent one was considered the index test. The complete set of analytes is listed in [Table 2](#tbl2){ref-type="table"}. For each of the analytes, we compared the mean value of the cases and controls and assessed the significance of the difference using a *t*-test. We then considered the distribution of each test parameter in the control group, arranging the controls into five quintiles of equal size. We compared the distribution of cases and controls by quintile and then calculated the odds ratio for the high-risk quintile, relative to the reference quintile. The reference quintile was either the top or the bottom quintile and was chosen *post hoc* as the one which was associated with an odds ratio above unity.

Generating a logistic regression model to choose the lab tests that contribute to CRC prediction (feature selection)
--------------------------------------------------------------------------------------------------------------------

To reduce the number of analytes into a small reference panel of parameters that carried the most information, for each individual we assigned a value of one for those in the high-risk category or zero for those in the low-risk category or with a missing value. To account for correlation between analytes within a functional group (as defined in [Table 2](#tbl2){ref-type="table"}) we applied a logistic regression model to the parameters within that group and then flagged those analytes that were statistically significant. From this set (all groups combined) we then generated a final regression model that included only those lab tests that showed significant difference (*P*\<0.0001) and for which the odds ratio exceeded 1.5. There were nine variables in the canonical sets for men and women. We created a CRC score for each individual, which ranged from zero to nine, based on the number of risk factors. We then compared the distribution of the CRC scores for cases and controls for men and for women and we generated odds ratios for each risk score, using the reference level of zero.

The CRC risk score was developed using cancer cases diagnosed at all stages using values from the blood test most recently acquired before diagnosis. We wished to evaluate the potential for using the CRC risk score to identify CRC cases diagnosed at an early (i.e., treatable) stage as well as to predict the development of CRC in the future. First, we repeated the analysis, restricting the cases to early-stage (localised) CRC. Second, we generated the distribution of the risk score for analytes for lab tests taken at various time windows before the index date to see to what extent the risk score predicted the risk of developing CRC up to 3 years in the future.

### Evaluating sensitivity and specificity

We evaluated the overall performance of the risk score for predicting CRC in the entire MHS population. We assigned a risk score for each individual in the MHS database. We then calculated the performance of the score for different age groups and the score cutoffs for unmatched population (all controls).

Results
=======

There were 102 775 subjects in the electronic medical record of MHS ([Table 1](#tbl1){ref-type="table"}). Of these, 2294 (2.2%) were diagnosed with CRC between the ages of 40 and 75 years in the period of diagnosis 2002 to 2011. Of these, 1755 cases (77%) had one or more blood test recorded during the period 30--180 days before diagnosis. Of the 1755 eligible CRCs, 716 were distal, 367 were proximal and 539 were rectal cancers (unknown 133). Of the 1755 CRCs, 450 were localised (26%), 774 were regional (44%) and 93 had distant metastases (5.3%) (438 other or stage unknown). Each case was matched to 45 controls.

We studied 30 analytes in five groups. The cases and controls were compared for all 30 analytes using a *t*-test ([Table 2](#tbl2){ref-type="table"}). We then selected those analytes that were most helpful in discriminating between cases and controls, by generating odds ratios using the logistic regression model, based on the distribution of cases and controls in the highest risk quintile, *vs* the bottom quintile.

To generate the final model, we incorporated nine analytes. The nine analytes were selected from the various groupings based on the odds ratios (\>1.5) and the corresponding *P*-values (\<0.0001). For each of the analytes, we estimated the odds ratio for an individual in the high-risk quintile, compared with all other individuals. The (mutually adjusted) odds ratios associated with the high-risk quintile for the analytes in the canonical panel (*vs* all others) ranged from 1.7 (for low protein, females) to 6.0 (for low iron, females) ([Table 3](#tbl3){ref-type="table"}).

Finally, a risk score was generated for each individual, which was based on the total number of risk factors that an individual carried ([Table 4](#tbl4){ref-type="table"}). Among controls, the mean risk score was 1.23 for men and was 1.25 for women. Among cases, the mean risk score was 2.62 for men and was 2.86 for women. Among men, the odds ratios associated with risk scores above zero ranged from 1.5 for those with a risk score of one to 233 for those with a risk score of eight or nine. Among women, the odds ratios associated with risk scores above zero ranged from 1.5 for those with a risk score of one to 76 for those with a risk score of eight or nine. The odds ratio for a risk score of four or greater for men (*vs* three or less) was 7.3 (95% CI: 6.3--8.5). The odds ratio for a risk score of four or more for women (*vs* three or less) was 7.8 (95% CI: 6.7--9.1). For localised cancer, the odds ratio of a risk score of four or greater for men (*vs* three or less) was 6.1 (95% CI: 4.6--8.2) and the odds ratio for a risk score of four or more for women (*vs* three or less) was 5.0 ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

It is hoped that the test could be used to identify cancers well in advance of clinical symptoms. We analysed the predictive value (odds ratio) for risk scores based on blood values taken in advance of the date of diagnosis ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Using a cutoff of 4+ for women, the odds ratio was 4.95 (95% CI: 4.1--6.0) for the period 90--180 days before diagnosis, was 3.2 (95% CI: 2.7--3.9) for 180 days to 1 year, was 2.3 (95% CI: 1.9--2.8) for 1--2 years and was 1.3 (95% CI: 1.0--1.7) for 2--3 years ([Table 5](#tbl5){ref-type="table"}). Using a cutoff of 4+ for men, the odds ratio was 5.1 (95% CI: 4.2--6.2) for the period 90--180 days before diagnosis, was 3.5 (95% CI: 2.8--4.2) for 180 days to 1 year, was 2.1 (95% CI: 1.7--2.6) for 1--2 years and was 1.3 (95% CI: 1.0--1.6) for 2--3 years.

To estimate the sensitivity of the high-risk score at a specificity of 95%, we used the entire MHS database ([Table 6](#tbl6){ref-type="table"}). Using a cutoff level of risk score of 4+ for men, the sensitivity was 31%, the specificity was 95% and the positive predictive value of an abnormal score was 7.3%. For women, using a cutoff of 5+, the sensitivity was 24%, the specificity was 95% and the positive predictive value was 4.2%.

Discussion
==========

We show that information abstracted from the electronic medical records of a large health-care provider can be adapted to identify a sub-population at risk of having CRC up to 2 years before diagnosis. We generated a CRC score, which varied from zero to nine, based on laboratory values that were recorded for a minimum of 10% of the subjects. As the risk score increased, the odds ratio for a cancer being diagnosed in the near term (30--180 days post-test) increased greatly. A score of four or more was associated with an odds ratio of 7.3 for men and of 7.8 for women, respectively. For subjects with the highest risk scores, the odds ratios exceeded 50. At a specificity of 95%, the sensitivity of a CRC score was 31% for men and was 24% for women. Among those in the top 5% of the CRC score, the positive predictive value for colon cancer was 7.3% for men and 4.2% for women.

In the MHS health plan, 2294 of 379 701 individuals, aged 40--75 years (36%) were diagnosed with CRC from 2002 to 2011 ([Table 1](#tbl1){ref-type="table"}). That is, the annual incidence of CRC was 61 per 100 000 per year -- in contrast to the incidence of 600 per 100 000 per year among those individuals with a CRC score of five or more.

There are limitations to our study. This is a large observational study and the data were collected for clinical care and monitoring health-care services and was not designed for the purposes of evaluating screening. As a consequence, the data on the laboratory values and the CRC diagnoses were less detailed than we would have liked. The blood samples were taken at various time intervals before cancer diagnosis and blood collection was not standardised. The levels for many of the analytes vary over time and each analyses were based on a single test result per subject. Furthermore, the tests were ordered by the treating physicians for various clinical reasons, largely unrelated to CRC. For example, the mean number of analytes for which information was available was 6.5 for the male cases and was 6.2 for the male controls (out of nine) and the mean number of analytes was 6.7 for the female cases and was 6.4 for the female controls (out of nine). Ideally, we would have had a complete data set for each case and each control. However, it is a testament to the strength of this approach that we were able to generate significant and large risk ratios despite a high level of missing values. Further, the goal of our initiative is to provide a prescreening tool to health-care institutions that can be implemented immediately using existing medical records and at little cost. We did not incorporate other factors in the model such as age, family history of cancer, BMI, or aspirin use, previous colonoscopies or adenomatous polyps.

Our study is similar to a previous study of [@bib2], which was conducted using a UK-based data set (THIN). In that study, which included 13 879 colon cancer cases and 54 109 matched controls, the risk model contained several of the haematologic variables we have included here, including red blood cell counts and neutrophils. In that study, the odds ratio for individuals in the highest *vs* the lowest risk decile was 18. In comparison, in our study, for individuals in the highest decile, the odds ratio was ∼28. For both the studies, the discriminatory power greatly exceeded that of previous models based on demographic factors and other risk factors ([@bib14]; [@bib21]; [@bib11]).

The specific components of the CRC score fall into three principal categories: iron deficiency, inflammation and thrombosis, and liver function. Those individuals in the lowest quintile of haemoglobin level (\<13.5 for men and \<12.2 for women) were at increased risk for the development of CRC, presumably due to occult colonic bleeding, but the magnitude of the associations using haemoglobin alone (odds ratios three to four) were much less than those generated using the CRC score. There were also very strong and independent associations with low levels of serum iron and ferritin, which also contributed to risk beyond that of haemoglobin and red cell morphology. A high platelet count (top quintile *vs* others) was associated with a three-fold increased risk of CRC. Platelets have been implicated in CRC carcinogenesis and progression in several studies, although the exact mechanism by which platelets contribute to CRC incidence and metastasis is not known ([@bib10]; [@bib18]). Possible mechanisms include transport of cancer cells through intravasation and extravasation in and out of vessels and promoting cancer cell aggregation ([@bib20]; [@bib18]; [@bib16]). Platelets also induce epithelial--mesenchymal transition of cancer cells, thereby enhancing their metastatic ability ([@bib16]). Importantly, there is now compelling evidence that daily low-dose aspirin is an effective chemoprevention agent against CRC ([@bib5]; [@bib17]; [@bib4]). It is proposed that the protective effect of aspirin works through the inhibition of platelet activation at GI mucosal lesions during the early stages of colorectal carcinogenesis ([@bib22]; [@bib6]; [@bib16]). We hope to replicate the findings of the current study using other populations and to conduct studies to confirm the potential of our preliminary findings in terms of facilitating the early diagnosis of cancer.

We were able to predict cancers up to 2 years in advance of the clinical diagnosis using the CRC score, but after 2 years the discriminant ability fell off. One would expect that a 2-year advance in the date of diagnosis would be of clinical utility, and it is encouraging that the CRC score effectively predicted the presence of localised cancer; it is expected that the majority of these cases are curable ([@bib8]). The risk score was performed optimally for the time window from 30 to 180 days before diagnosis, but it was also predictive of cancer 2 years in the future; this lends support to the hope that this can be a useful adjunct to the early detection of CRC. Also, screening colonoscopy is not routinely recommended to men or women before age 50 years; in the age group 40--50 years, those with a CRC score of six or greater had a high risk of CRC that was comparable or greater to much older individuals ([Table 5](#tbl5){ref-type="table"}) and it is rational to consider that screening colonoscopy may be extended to this small high-risk subgroup.

The data presented here support the principle that information contained in the laboratory record of a large health services organisation can be used to predict the risk of CRC. Within these large databases, information that is relevant to clinical care may not be apparent using clinical judgment alone but might be exploited using electronic medical records and statistical methodologies. Valuable information may be obtained by interpreting multiple analytes that may fall within the clinical norms. In this study, we use simplified statistical tools designed into an innovative scoring model to document the performance of a CRC score. Through the use of machine learning on a wide set of analytes, we hope to significantly improve test performance.

The future use of machine learning is expected to allow us to handle blood test values in a continuous (rather than discrete) way, to provide different weights to each test, and to combine the test values in a nonlinear and complex manner.

It is to be determined if the reporting of the scoring to the treating physician will improve adherence and compliance with current screening guidelines.
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###### 
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###### Characteristics of cases and controls

                                       **Cases**   **Controls**
  ----------------------------------- ----------- --------------
  Number of patients                     2294        102 775
  Age at index blood test                62.2          61.5
  Males                                  1226         55 000
  Females                                1068         47 775
  Year of birth                         1943.8        1944.4
  Age at colon cancer (years)            62.6            
  Localised                               568            
  Regional                               1020            
  Distant                                 118            
  Other                                   588            
  Date of diagnosis of colon cancer     2006.5           

###### All analytes

  **Blood test**                        **Cases** **Mean**   **Controls** **Mean**   **RR (high-risk quintile** ***vs*** **low-risk quintile)**   ***P*****-value (*****t*****-test)**
  ------------------------------------ -------------------- ----------------------- ------------------------------------------------------------ --------------------------------------
  **Females**                                                                                                                                    
  Haematology                                                                                                                                                       
   Basophils                                   0.03                  0.03                                1.19 (1.02--1.48)                                       0.0003
   Eosinophils                                 0.21                  0.18                                2.03 (1.58--2.79)                                      \<0.0001
   Haemoglobin                                 11.8                  13.02                               5.69 (4.31--7.97)                                      \<0.0001
   Lymphocytes                                 2.25                  2.21                                1.37 (1.06--1.78)                                        0.43
   Mean corpuscular volume                    84.50                  88.64                               3.52 (2.84--4.39)                                      \<0.0001
   Monocytes                                   0.56                  0.51                                1.99 (1.63--2.65)                                      \<0.0001
   Mean platelet volume                       10.78                  11.06                               2.33 (1.72--3.26)                                      \<0.0001
   Neutrophils                                 4.33                  3.70                                3.02 (2.42--4.17)                                      \<0.0001
   Platelets                                   301                    254                                3.87 (3.09--5.21)                                      \<0.0001
   Red blood cell count                        4.39                  4.48                                1.97 (1.51--2.61)                                      \<0.0001
   Red blood cell distribution width          14.81                  13.71                               4.54 (3.58--6.26)                                      \<0.0001
   White blood cell count                      7.46                  6.65                                2.17 (1.66--3.02)                                      \<0.0001
  Liver function                                                                                                                                                    
   Alkaline phosphatase                       92.37                  76.39                               2.43 (1.75--3.33)                                      \<0.0001
   Alanine aminotransferase                   18.94                  21.91                                3.12 (2.45--4.2)                                      \<0.0001
   Aspartate aminotransferase                 21.23                  22.64                                2.45 (1.82--3.2)                                       0.011
   Bilirubin                                   0.52                  0.60                                2.31 (1.71--3.25)                                      \<0.0001
   *γ*-Glutamyl transferase                   58.76                  38.35                               1.42 (1.04--2.15)                                        0.10
  Metabolic                                                                                                                                                         
   Albumin                                     4.08                  4.22                                2.62 (1.91--3.44)                                      \<0.0001
   Cholesterol                                 201                    210                                1.77 (1.29--2.39)                                      \<0.0001
   Glucose                                     110                    109                                 1.2 (1.03--1.74)                                        0.28
   Haemoglobin A1c                             6.57                  6.65                                  1.06 (1--1.75)                                         0.16
   Lactic acid dehydrogenase                   375                    351                                1.32 (1.04--2.57)                                        0.17
   Low-density lipoprotein                     121                    126                                 1.4 (1.09--1.86)                                      0.00082
   Protein                                     7.11                  7.28                                2.12 (1.54--3.08)                                      \<0.0001
   Prothrombin time (%)                       15.00                  15.47                                 4.58 (2.97--8)                                         0.44
   Partial thromboplastin time                25.97                  27.19                               1.75 (1.06--4.13)                                      0.00016
  Other                                                                                                                                                             
   Fe -- iron                                 46.84                  77.22                                16 (9.14--33.4)                                       \<0.0001
   Ferritin                                   46.24                  69.62                               4.59 (3.06--7.73)                                      \<0.0001
  Vitamins                                                                                                                                                          
   Folic acid                                  4.33                  4.43                                1.91 (1.28--2.96)                                        0.37
   Vitamin B12                                 430                    426                                  1.07 (1--1.54)                                         0.40
  **Males**                                                                                                                                      
  Haematology                                                                                                                                                       
   Basophils                                   0.03                  0.03                                 1.4 (1.14--1.75)                                       0.0017
   Eosinophils                                 0.25                  0.22                                1.62 (1.29--2.04)                                      \<0.0001
   Haemoglobin                                 13.3                  14.43                               3.77 (2.66--5.08)                                      \<0.0001
   Lymphocytes                                 2.13                  2.21                                1.17 (1.01--1.53)                                       0.026
   Mean corpuscular volume                     85.7                  88.90                                3.44 (2.7--4.87)                                      \<0.0001
   Monocytes                                   0.68                  0.61                                 2.11 (1.74--2.8)                                      \<0.0001
   Mean platelet volume                       10.78                  11.07                                2.33 (1.8--2.93)                                      \<0.0001
   Neutrophils                                 4.69                  4.13                                2.29 (1.73--2.96)                                      \<0.0001
   Platelets                                   261                    222                                3.78 (2.95--4.88)                                      \<0.0001
   Red blood cell count                        4.76                  4.87                                1.75 (1.45--2.24)                                      \<0.0001
   Red blood cell distribution width          14.26                  13.61                               2.87 (2.23--3.78)                                      \<0.0001
   White blood cell count                      7.79                  7.20                                2.31 (1.87--3.05)                                      \<0.0001
  Liver function                                                                                                                                                    
   Alkaline phosphatase                         86                   73.36                               2.76 (2.21--3.88)                                      \<0.0001
   Alanine aminotransferase                   20.97                  25.61                               3.61 (2.69--4.72)                                      \<0.0001
   Aspartate aminotransferase                 21.19                  23.77                               2.75 (2.17--3.88)                                      \<0.0001
   Bilirubin                                   0.63                  0.74                                 2.71 (1.9--3.72)                                      \<0.0001
   *γ*-Glutamyl transferase                   59.73                  45.92                               1.29 (1.02--2.03)                                       0.026
  Metabolic                                                                                                                                                         
   Albumin                                     4.19                  4.30                                 1.97 (1.5--2.55)                                      \<0.0001
   Cholesterol                                 184                  189.48                                1.46 (1.1--1.9)                                       0.00038
   Glucose                                     112                    114                                  1.13 (1--1.43)                                        0.046
   Haemoglobin A1c                             6.76                  6.74                                  1.07 (1--1.67)                                         0.40
   Lactic acid dehydrogenase                   332                    341                                1.64 (1.05--3.57)                                        0.24
   Low-density lipoprotein                     113                    116                                1.28 (1.02--1.55)                                       0.044
   Protein                                     7.20                  7.30                                2.62 (1.81--3.58)                                      0.00034
   Prothrombin time (%)                       21.32                  22.63                                 3 (2.07--4.67)                                         0.33
   Partial thromboplastin time                27.85                  28.55                               1.61 (1.04--3.17)                                       0.079
  Other                                                                                                                                                             
   Fe -- iron                                 54.68                  84.35                               5.38 (3.36--9.08)                                      \<0.0001
   Ferritin                                   73.53                 124.84                               4.95 (3.22--8.45)                                      \<0.0001
  Vitamins                                                                                                                                                          
   Folic acid                                  4.42                  4.46                                1.53 (1.06--2.52)                                        0.44
   Vitamin B12                                 381                    393                                 1.39 (1.02--2.5)                                        0.16

Abbreviation: RR=risk ratio.

###### Final model (logistic regression)

  **Blood test**                        **High-risk quintile**   **RR (95% CI)**  **95% CI**    ***P*****-value**
  ------------------------------------ ------------------------ ----------------- ------------ -------------------
  **Females**                                                                                  
  Haematology                                                                                            
   Haemoglobin                                    5                   3.83        3.38--4.46        \<0.0001
   Mean corpuscular volume                        5                   3.04        2.7--3.54         \<0.0001
   Neutrophils                                    1                   2.03        1.82--2.35        \<0.0001
   Platelets                                      1                   2.95        2.56--3.35        \<0.0001
   Red blood cell distribution width              1                   3.14        2.81--3.66        \<0.0001
  Liver function                                                                                         
   Alanine aminotransferase                       5                   1.83        1.6--2.14         \<0.0001
  Metabolic                                                                                              
   Protein                                        5                   1.71        1.42--2.01        \<0.0001
  Other                                                                                                  
   Fe -- iron                                     5                   6.01        5.08--7.08        \<0.0001
   Ferritin                                       5                   5.04        4.47--6.26        \<0.0001
  **Males**                                                                                    
  Haematology                                                                                            
   Haemoglobin                                    5                   3.06        2.76--3.52        \<0.0001
   Mean corpuscular volume                        5                   2.98        2.58--3.42        \<0.0001
   Monocytes                                      1                   1.85        1.6--2.12         \<0.0001
   Platelets                                      1                   2.84        2.5--3.27         \<0.0001
  Liver function                                                                                         
   Alkaline phosphatase                           1                   2.10        1.79--2.34        \<0.0001
   Alanine aminotransferase                       5                   2.09        1.82--2.36        \<0.0001
   Aspartate aminotransferase                     5                   1.77        1.52--2.04        \<0.0001
  Other                                                                                                  
   Fe -- iron                                     5                   5.44        4.47--6.16        \<0.0001
   Ferritin                                       5                   5.75        4.74--6.9         \<0.0001

Abbreviations: CI=confidence interval; RR=risk ratio.

###### Distribution of risk scores for cases and controls with associated odds ratios

  **Score**      **Controls**   **Cases**   **% of Cases**   **Odds ratio**  **95% CI**
  ------------- -------------- ----------- ---------------- ---------------- --------------
  **Females**                                                                
  0                  9643          127            16              1.00       0.78--1.28
  1                  7628          146            18              1.45       1.14--1.85
  2                  4590          137            17              2.27       1.78--2.89
  3                  2470          98             12              3.01       2.31--3.94
  4                  1129          111            14              7.47       5.74--9.7
  5                  513           76             9              11.25       8.35--15.15
  6                  193           79             10             31.08       22.68--42.58
  7                   59           31             4              39.89       24.97--63.75
  8/9                 14           14             1              75.93       35.46--1626
  Total             26 239         819           100                          
  **Males**                                                                  
  0                 10 259         147            16              1.00       0.79--1.26
  1                  8302          180            19              1.51       1.21--1.89
  2                  5438          164            18              2.10       1.68--2.64
  3                  2834          154            16              3.79       3.01--4.77
  4                  1080          113            12              7.30       5.67--9.41
  5                  398           90             10             15.78       11.92--20.9
  6                  135           48             5              24.81       17.18--35.83
  7                   42           30             3              49.85       30.36--81.86
  8/9                 3            10             1              232.6       63.37--854.2
  Total             28 491         936           100                          

Abbreviation: CI=confidence interval.

###### Odds ratios for colorectal cancer associated with a risk score of four or more (*vs* three or less), by time period before diagnosis

  **Time period before diagnosis**    **Odds ratio for CRC (risk score 4--9** ***vs*** **0--3)**  **95% CI**
  ---------------------------------- ------------------------------------------------------------ ------------
  **Females**                                                                                     
  30--180 days                                                   7.8                              6.7--9.1
  90--180 days                                                   5.0                              4.1--6.0
  180 days to 1 year                                             3.2                              2.7--3.9
  1--2 years                                                     2.3                              1.9--2.8
  2--3 years                                                     1.3                              1.0--1.7
  **Males**                                                                                        
  30--180 days                                                   7.3                              6.3--8.5
  90--180 days                                                   5.1                              4.2--6.2
  180 days to 1 year                                             3.5                              2.8--4.2
  1--2 years                                                     2.1                              1.7--2.6
  2--3 years                                                     1.3                              1.0--1.6

Abbreviation: CI=confidence interval.

###### Characteristics of screening test

  **Cutoff**      **False negatives**   **True Negatives**   **False positives**   **True positives**   **Total**   **Specificity**   **Sensitivity**
  -------------- --------------------- -------------------- --------------------- -------------------- ----------- ----------------- -----------------
  **Females**                                                                                                                        
  All ages                                                                                                                                    
   ⩾6                     695                 90 533                1654                  124            93 006          98.2%              15%
   ⩾5                     619                 87 681                4506                  200            93 006          95.1%              24%
   ⩾4                     508                 82 099               10 088                 311            93 006          89.1%              38%
  40--50 years                                                                                                                                
   ⩾6                     58                  40 747                1152                   13            41 970          97.3%              18%
   ⩾5                     47                  38 885                3014                   24            41 970          92.8%              34%
   ⩾4                     37                  35 387                6512                   34            41 970          84.5%              48%
  50--60 years                                                                                                                                
   ⩾6                     190                 25 521                 292                   35            26 038          98.9%              16%
   ⩾5                     171                 25 022                 791                   54            26 038          96.9%              24%
   ⩾4                     139                 23 979                1834                   86            26 038          92.9%              38%
  60--70 years                                                                                                                                
   ⩾6                     297                 17 274                 128                   35            17 734          99.3%              11%
   ⩾5                     270                 16 978                 424                   62            17 734          97.6%              19%
   ⩾4                     231                 16 353                1049                  101            17 734          94.0%              30%
  70--75 years                                                                                                                                
   ⩾6                     150                  6991                  82                    41             7264           98.8%              21%
   ⩾5                     131                  6796                  277                   60             7264           96.1%              31%
   ⩾4                     101                  6380                  693                   90             7264           90.2%              47%
  **Males**                                                                                                                          
  All ages                                                                                                                                    
   ⩾6                     848                 71 285                 314                   88            72 535          99.6%              9%
   ⩾5                     758                 70 454                1145                  178            72 535          98.4%              19%
   ⩾4                     645                 67 923                3676                  291            72 535          94.9%              31%
  40--50 years                                                                                                                                
   ⩾6                     72                  30 532                 102                   14            30 720          99.7%              16%
   ⩾5                     68                  30 292                 342                   18            30 720          98.9%              21%
   ⩾4                     58                  29 322                1312                   28            30 720          95.7%              33%
  50--60 years                                                                                                                                
   ⩾6                     199                 21 325                 81                    11            21 616          99.6%              5%
   ⩾5                     179                 21 092                 314                   31            21 616          98.5%              15%
   ⩾4                     154                 20 409                 997                   56            21 616          95.3%              27%
  60--70 years                                                                                                                                
   ⩾6                     346                 13 959                 80                    36            14 421          99.4%              9%
   ⩾5                     305                 13 716                 323                   77            14 421          97.7%              20%
   ⩾4                     267                 13 142                 897                  115            14 421          93.6%              30%
  70--75 years                                                                                                                                
   ⩾6                     231                  5469                  51                    27             5778           99.1%              10%
   ⩾5                     206                  5354                  166                   52             5778           97.0%              20%
   ⩾4                     166                  5050                  470                   92             5778           91.5%              36%
